Medicines labeled for the same conditions
Alternatives to meropenem and vaborbactam
13 other medicines are given the same way (intravenous) and in the same FDA class as meropenem and vaborbactam or labeled mainly for the same use (urinary tract infections); 4 are in its class, penem antibacterials: cilastatin and imipenem, avibactam and ceftazidime, ceftolozane and tazobactam and cilastatin and imipenem and relebactam; the others include 5 cephalosporin antibacterials and 2 tetracycline-class drugs (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as meropenem and vaborbactam?
Urinary tract infections lists all 39 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Meropenem and vaborbactampenem antibacterial | this medicine | none listed | n/a | No | No current entry |
| Cilastatin and imipenemrenal dehydropeptidase inhibitor · same class | Urinary tract infections | 2 labelers | n/a | No | A presentation being discontinued |
| Avibactam and ceftazidimebeta lactamase inhibitor · same class | Urinary tract infections | none listed | n/a | No | No current entry |
| Ceftolozane and tazobactambeta lactamase inhibitor · same class | Urinary tract infections | none listed | n/a | No | No current entry |
| Cilastatin and imipenem and relebactamrenal dehydropeptidase inhibitor · same class | Urinary tract infections | none listed | n/a | No | A presentation being discontinued |
| Doxycyclinetetracycline-class drug | Urinary tract infections | 20 labelers | n/a | No | A presentation being discontinued |
| Cefazolincephalosporin antibacterial | Urinary tract infections | 7 labelers | $1.07 per vial 1 g vial | No | No current entry |
| Cefepimecephalosporin antibacterial | Urinary tract infections | 8 labelers | n/a | No | A presentation being discontinued |
| Ceftriaxonecephalosporin antibacterial | Urinary tract infections | 7 labelers | $1.44 per vial 1 g vial | No | No current entry |
| Plazomicin | Urinary tract infections | none listed | n/a | Yes | No current entry |
| Cefepime and zidebactamcephalosporin antibacterial | Urinary tract infections | none listed | n/a | No | No current entry |
| Cefiderocolcephalosporin antibacterial | Urinary tract infections | none listed | n/a | No | No current entry |
| Fosfomycin | Urinary tract infections | none listed | n/a | No | No current entry |
| Minocyclinetetracycline-class drug | Urinary tract infections | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Meropenem and vaborbactam: the full record
- label, generics, price, shortages, recalls